Future Direction of Lab Medicine – Upcoming

Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

Join Mayo Clinic Laboratories for our webinar exploring the expanding role of precision diagnostics in the evaluation of serious and potentially life-threatening infections. Focusing on metagenomic sequencing available from Mayo Clinic Laboratories, including the Karius Spectrum plasma test, which is offered by Mayo Clinic Laboratories in collaboration with Karius, participants will gain an overview of microbial cell-free DNA (mcfDNA) metagenomic sequencing, including clinical decision-making around test ordering, appropriate clinical indications, and how to interpret and apply results to support timely diagnosis and patient management.

Recording coming soon. Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.